Wirth Angela
Max-Planck-Institute for Heart and Lung Research, Dept. of Pharmacology, Ludwigstraße 43, 61231 Bad Nauheim, Germany.
Biochim Biophys Acta. 2010 Dec;1802(12):1276-84. doi: 10.1016/j.bbadis.2010.05.002. Epub 2010 May 9.
Arterial hypertension is a multifactorial disease that is characterised by increased peripheral vascular resistance often accompanied by smooth muscle cell hypertrophy and proliferation. Rho kinases (ROCKs) are the most extensively studied effectors of the small G-protein RhoA and abnormalities in RhoA/ROCK signalling have been observed in various cardiovascular disease including hypertension. The RhoA/ROCK-pathway is a key player in different smooth muscle cell functions including contractility, proliferation and migration. Furthermore, there is extensive crosstalk between RhoA/ROCK- and NO-signalling. Therefore, not only ROCK inhibitors but also NO-donators or pleiotropic agents like statins exert their beneficial effects on the cardiovascular system at least in part via Rho/Rho-kinase.
动脉高血压是一种多因素疾病,其特征是外周血管阻力增加,常伴有平滑肌细胞肥大和增殖。Rho激酶(ROCKs)是对小G蛋白RhoA研究最为广泛的效应器,在包括高血压在内的各种心血管疾病中均观察到RhoA/ROCK信号异常。RhoA/ROCK信号通路是不同平滑肌细胞功能(包括收缩性、增殖和迁移)的关键参与者。此外,RhoA/ROCK信号与NO信号之间存在广泛的相互作用。因此,不仅ROCK抑制剂,而且NO供体或他汀类等多效性药物至少部分通过Rho/Rho激酶对心血管系统发挥有益作用。